Elevated high-sensitivity cardiac troponin T (>0.014 ng/mL) independently predicted progression to end-stage hypertrophic cardiomyopathy, which occurred in 8.3% of patients over 6.3 years.
Cohort (n=157)
Does elevated hs-cTnT predict progression to end-stage HCM and left ventricular remodeling in patients with hypertrophic cardiomyopathy?
Elevated hs-cTnT is an independent predictor of progression to end-stage hypertrophic cardiomyopathy and left ventricular remodeling.
AIMS: Hypertrophic cardiomyopathy (HCM) is generally associated with mild disability and normal life expectancy. On the other hand, once the end-stage phase of HCM characterized by left ventricular (LV) ejection fraction 1 year. HCM progressed to end-stage HCM in 13 patients (8.3%) of the 157 patients during a mean follow-up period of 6.3 ± 2.8 years. Compared with patients who did not reach end-stage HCM at the last evaluation, patients with progression to the end-stage phase had lower ejection fraction, larger LV size, more enlarged left atrial diameter, longer follow-up period, and higher frequency of an elevated concentration of high-sensitivity cardiac troponin T (hs-cTnT; >0.014 ng/mL) at registration. Multivariate analysis revealed that elevated hs-cTnT was a significant predictor independent of lower LV ejection fraction for progression to end-stage HCM. Furthermore, in patients with elevated hs-cTnT levels, LV ejection fraction became significantly lower, LV end-diastolic diameter increased, and LV wall thickness decreased during the follow-up period, whereas those parameters did not change in the normal hs-cTnT group. CONCLUSIONS: In patients with HCM, an elevated hs-cTnT was associated with progression of LV remodelling, and this biomarker can be useful for predicting progression to the end-stage phase.
Kubo et al. (Mon,) conducted a cohort in Hypertrophic cardiomyopathy (HCM) (n=157). Elevated high-sensitivity cardiac troponin T (hs-cTnT >0.014 ng/mL) vs. Normal hs-cTnT was evaluated on Progression to end-stage HCM. Elevated high-sensitivity cardiac troponin T (>0.014 ng/mL) independently predicted progression to end-stage hypertrophic cardiomyopathy, which occurred in 8.3% of patients over 6.3 years.